



Freedom of Information Request

I am analysing the treatment of lung cancer and would greatly appreciate if you could answer the following questions:

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

. Afatinib	5
. Alectinib	0
. Atezolizumab monotherapy	4
. Atezolizumab with chemotherapy	0
. Bevacizumab	0
. Brigatinib	0
. Ceritinib	1
. Crizotinib	0
. Dacomitinib	1
. Dabrafenib with Trametinib	1
. Docetaxel monotherapy or combination with Carboplatin/Cisplatin	0
. Durvalumab	5
. Erlotinib	0
. Gefitinib	3
. Gemcitabine	1
. Lorlatinib	1
. Nintedanib with Docetaxel	0
. Nivolumab	0
. Osimertinib	3
. Paclitaxel	0
. Pembrolizumab monotherapy	8
. Pembrolizumab with chemotherapy	6
. Pemetrexed with Carboplatin/Cisplatin	2
. Vinorelbine with Carboplatin/Cisplatin	0
. Any other active systemic anti-cancer therapy (SACT)	0
. Palliative care only -	unknown

Q2. In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:

. Atezolizumab monotherapy	1
. Atezolizumab with chemotherapy	0
. Durvalumab	3
. Gemcitabine	0



· Nivolumab	0
· Osimertinib	0
· Paclitaxel	0
· Pembrolizumab (Keytruda) Mono	4
· Pembrolizumab (Keytruda) with Chemotherapy	2
· Other active systemic anti-cancer therapy (SACT)	0
· Palliative care only	unknown

Q3. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?

No.